EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits

Chi Kin Wong, Daniel J Drucker

Journal of Clinical Investigation · 03.11.2025 · 135 (21)

DOI: 10.1172/jci194751 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.11.2025. Verfasst von Chi Kin Wong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Diabetes Mellitus, Type 2, Anti-Inflammatory Agents. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss–dependent and –independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines. In this Review, we highlight current understanding of the direct and indirect antiinflammatory effects and mechanisms of GLP-1 medicines in both preclinical and clinical studies, covering emerging concepts, clinical relevance, and areas of uncertainty that require further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Diabetes Mellitus, Type 2Anti-Inflammatory AgentsHumansAnimalsMiceGlucagon-Like Peptide-1 ReceptorObesityInflammationSignal TransductionGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

Glucagon-Like Peptide 1Anti-Inflammatory AgentsGlucagon-Like Peptide-1 ReceptorGLP1R protein, humanGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
  • Department of Medicine, University of Toronto, Ontario, Canada.

Zitieren

APA

Wong, C. K., & Drucker, D. J. (2025). Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. Journal of Clinical Investigation, 135(21). https://doi.org/10.1172/jci194751

Vancouver

Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits. Journal of Clinical Investigation. 2025;135(21). doi:10.1172/jci194751

BibTeX
@article{Wong2025,
  author = {Wong, Chi Kin and Drucker, Daniel J},
  title = {Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {21},
  doi = {10.1172/jci194751}
}
Kostenlos starten →